(0.38%) 5 037.57 points
(0.45%) 38 074 points
(0.74%) 15 721 points
(-0.44%) $78.65
(4.87%) $2.03
(0.01%) $2 311.20
(0.13%) $26.78
(0.71%) $961.65
(0.13%) $0.934
(0.07%) $11.04
(0.15%) $0.800
(-1.37%) $91.98
-1.61% $ 0.610
Live Chart Being Loaded With Signals
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage...
Stats | |
---|---|
Dzisiejszy wolumen | 335 019 |
Średni wolumen | 740 628 |
Kapitalizacja rynkowa | 404.31M |
EPS | $0 ( 2024-02-27 ) |
Last Dividend | $0.117 ( 2004-10-11 ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.330 |
ATR14 | $0.00100 (0.16%) |
Wolumen Korelacja
Opthea Ltd Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Opthea Ltd Korelacja - Waluta/Towar
Opthea Ltd Finanse
Annual | 2023 |
Przychody: | $161 163 |
Zysk brutto: | $-89 309.00 (-55.42 %) |
EPS: | $-0.450 |
FY | 2023 |
Przychody: | $161 163 |
Zysk brutto: | $-89 309.00 (-55.42 %) |
EPS: | $-0.450 |
FY | 2022 |
Przychody: | $125 047 |
Zysk brutto: | $-107 422 (-85.91 %) |
EPS: | $-0.340 |
FY | 2021 |
Przychody: | $68 613.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-0.195 |
Financial Reports:
No articles found.
Opthea Ltd Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.117 | 2004-10-11 |
Last Dividend | $0.117 | 2004-10-11 |
Next Dividend | $0 | N/A |
Payout Date | 2004-11-01 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.117 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0.0275 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
RFF.AX | Ex Dividend Knight | 2023-09-28 | Quarterly | 0 | 0.00% | |
BRG.AX | Ex Dividend Knight | 2023-09-13 | Semi-Annually | 0 | 0.00% | |
KSL.AX | Ex Dividend Knight | 2023-09-06 | Semi-Annually | 0 | 0.00% | |
SRV.AX | Ex Dividend Knight | 2023-09-04 | Semi-Annually | 0 | 0.00% | |
COH.AX | Ex Dividend Knight | 2023-09-18 | Annually | 0 | 0.00% | |
MXT.AX | Ex Dividend Knight | 2023-08-31 | Monthly | 0 | 0.00% | |
WBC.AX | Ex Dividend Junior | 2023-05-11 | Annually | 0 | 0.00% | |
EHL.AX | Ex Dividend Knight | 2023-09-07 | Sporadic | 0 | 0.00% | |
PCG.AX | Ex Dividend Junior | 2023-08-29 | Annually | 0 | 0.00% | |
ALU.AX | Ex Dividend Knight | 2023-09-04 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -1 383.77 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -1.467 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | 8.77 | 1.500 | 10.00 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 5.10 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 5.00 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 4.82 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.000780 | -1.500 | 9.99 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -8.08 | 1.000 | -4.10 | -4.10 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.306 | 2.00 | -0.102 | -0.204 | [0 - 30] |
freeCashFlowPerShareTTM | -0.306 | 2.00 | -0.153 | -0.306 | [0 - 20] |
debtEquityRatioTTM | -0.00277 | -1.500 | -0.0111 | 0.0166 | [0 - 2.5] |
grossProfitMarginTTM | 0.556 | 1.000 | 4.07 | 4.07 | [0.2 - 0.8] |
operatingProfitMarginTTM | -1 413.43 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -1 397.12 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.00106 | 0.800 | -3.33 | -2.66 | [0.5 - 2] |
Total Score | 0.0275 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -1.492 | 1.000 | -0.252 | 0 | [1 - 100] |
returnOnEquityTTM | 8.77 | 2.50 | 10.00 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.306 | 2.00 | -0.102 | -0.306 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.306 | 2.00 | -0.102 | -0.204 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.00740 | 1.500 | -3.28 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -1 027.63 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -0.559 |
Opthea Ltd
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema (DME), as well as a first in class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors to treat wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej